TFAP4/Wnt/β-catenin-IN-1

TFAP4/Wnt/β-catenin-IN-1 (Compound A61) is an orally active TFAP4/Wnt/β-catenin inhibitor. TFAP4/Wnt/β-catenin-IN-1 has significant anticancer activity against a variety of cancer cells (such as gastric cancer, lung cancer, breast cancer, etc.), and has the strongest anticancer activity against MGC-803 gastric cancer cells (IC50: 3.92 μM) . TFAP4/Wnt/β-catenin-IN-1 induces apoptosis and cell cycle arrest (S phase) in cancer cells by inhibiting the TFAP4/Wnt/β-catenin signaling pathway. TFAP4/Wnt/β-catenin-IN-1 can be used in the study of gastric cancer[1].

Product Specifications

UNSPSC

12352005

Target

Wnt; β-catenin

Related Pathways

Stem Cell/Wnt

Field of Research

Cancer

Smiles

BrC1=CC=C(C([H])C(C=C2/C=C/[C@H]3[C@@](CC[C@@H](O)[C@]4(CO)C)(C)C4CC=C3C)=NNC2=O)C=C1

Molecular Formula

C27H33BrN2O3

Molecular Weight

513.47

References & Citations

[1]Zhang H, et al. The development of pyridazinone-based andrographolide derivatives as anti-cancer agents with the ability of inhibiting the TFAP4/Wnt/β-catenin signaling pathway. Bioorg Chem. 2025 Jun 15;160:108440.